Obesity-Induced Alterations in Linezolid Tissue Distribution Revealed by Dynamic Positron Emission Tomography Imaging

Authors: Garcia-Varela, Lara; Gomez-Martinez, Maria; Bhol, Mamina; Esposito-Zapero, Claudia; Fernandez, Andrea; Cajade-Pascual, Francisco; Dorta, Valentina; Nogueiras, Ruben; Fernandez-Ferreiro, Anxo; Aguiar, Pablo; Llop, Jordi; Mondelo-Garcia, Cristina

Source journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2026-11-14)

DOI: 10.1016/j.ejps.2026.107721

Abstract

BACKGROUND: The rising prevalence of obesity and its associated susceptibility to infection raise concerns about the adequacy of fixed linezolid dosing. Obesity-related alterations in tissue drug exposure remain poorly characterised. This study quantified the in vivo biodistribution and pharmacokinetics of linezolid in diet-induced obese and control mice using positron emission tomography (PET). METHODS: Male C57BL/6J mice received a high-fat (n=6) or standard diet (n=8) for ten weeks. [(1)(8)F]F-Linezolid was produced by copper-mediated (1)(8)F-fluorination of a boronic ester precursor under optimised low-base conditions. Following intravenous administration, dynamic whole-body PET images were acquired over 90 minutes, followed by computed tomography (CT) imaging. Volumes of interest (brown and subcutaneous white adipose tissue, heart, knee, brain, and lung) were analysed using radioactivity concentration, total radioactivity, standardised uptake values, and kinetic modelling with an image-derived input function. Plasma radiometabolites were quantified by high-performance liquid chromatography. RESULTS: [(1)(8)F]F-Linezolid was obtained with >99% radiochemical purity and molar activity of 28-92 GBq/micromol. Obese mice showed lower blood radioactivity, with comparable parent-fraction profiles between groups. The one-tissue compartment model and Logan analysis provided optimal fits. Volume of distribution was significantly reduced in obese animals exclusively in adipose depots, accompanied by lower influx rate constants, whereas exposure was fully preserved in lung, brain, and bone/joint tissue. CONCLUSION: Obesity induces selective pharmacokinetic alterations confined to adipose compartments without compromising linezolid delivery to clinically relevant target tissues, revealing a plasma-tissue dissociation and a tissue-specific distribution that may limit the interpretation of plasma-based therapeutic drug monitoring.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.